Seeking Investment for Osteoarthritis Disease Modification Pharmaceutical

First-in-class, disease-modifying, once-a-year infusion for osteoarthritis
This Pennsylvania-based company’s asset disrupts current treatment of osteoarthritis
- Once per year intravenous infusion
- Controls pain
- Increases joint function
- Modifies the disease by reducing bone marrow lesions across multiple joints
Seeking investment of $25M-$30M to reach market (Full FDA approval), or Partnership to co-develop or license asset for specific application. Suitable for both human and animal health.
- Disease modification shown in human trial (Phase III)
- Relieves pain, increases joint mobility
- Applicable for multiple joints
- Once a year IV administration (as opposed to IA)
- Reformulation of approved compounds of known safety
- Zoledronic acid (ZA) + methylprednisolone (MP)
- Strong patent position through 2033 – 3 US and 4 International patents awarded thus far
No Comments